3-hrs Webinar Off Label Promotion for Drugs & Medical Devices

11:00 AM ET | 8:00 AM PT | 10:00 AM CT Duration 180 Minute

Webinar Includes : All the training handouts , Certificate by the Speaker ,Q/A and 180 Min Live Webinar

"Listen from Kelly Thomas she has 20 years’ experience in leading facility start-ups, PAI and Routine cGMP Surveillance inspections"

How FDA can reconcile

Description

FDA and industry have struggled for the past 10 years, with the question of how FDA can reconcile its mission to protect public health by ensuring that medical products distributed in the United States are safe and effective for their intended use, with the fact that there is both a public health imperative and a constitutional right for manufacturers of those products to share truthful and non-misleading information about those products with the public.

In the area of off-label information, there is a tension that arises from the fact that, while products are approved by FDA for specific uses, physicians are permitted to prescribe medical products for uses that are not approved by FDA; in some cases those unapproved uses are the standard of care. Similarly, payors are permitted – and in some cases required – to provide reimbursement for uses that FDA has not approved. Therefore, payors and healthcare providers require access to reliable information about these unapproved uses in order to make informed coverage and treatment decisions.

Court Cases citing First Amendment and Fifth Amendment rights have been discussed

To resolve this conundrum, the agency introduced 2 new guidance documents and a memorandum:

     a. Guidance: Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities—Questions and Answers

     b. Guidance: Medical Product Communications That Are Consistent With the FDA-Required Labeling—Questions and Answers.

     c. Memorandum: Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products

FDA invited comments concerning their comprehensive review of the regulations and policies governing manufacturer communications regarding unapproved uses of approved or cleared medical products. 

Why should you attend

Off Label Promotion for Drugs and Medical Devices is a controversial topic which often puts FDA and industry at loggerheads. FDA continues to need to ensure public health by protect public health by ensuring that medical products distributed in the United States are safe and effective for their intended use while industry believes that safe and effective off label use is warranted. It is further complicated by today’s patient who is much more savvy with regards to treatment and sometimes demands off-label use of products.

This class presents the latest FDA, industry & patient thinking to assist manufacturers in enhancing the predictability, consistency, and transparency of off-label promotion of medical products, and describing in greater detail the regulatory framework, policies, and practices underlying such a decision. The views of FDA, industry and patients will be presented and the latest concurrences and issues will be described.

Areas Covered

Session #: 1

Duration: 30 minutes

Learning Objectives: This session sets the context for the off-label promotion of medical products starting with early history and moving to the most recent history of FDA’s decision on guidance documents

      1. Early History of Off-Label Promotion of medical products including some common household products such as Listerine and Ketchup that were originally used for patient treatment

      2. Snake Oil Salesmen and the FDA

      3. FDA: between patients and industry

      4. Off-Label Promotions and First Amendment Issues

      5. Federal Register History of the current guidance documents

Session #: 2

Duration: 30 minutes 

Learning Objectives: As explained in the previous session FDA is always balancing the needs of the patient against the demands of the industry. Today’s patients create additional issues for FDA and industry in that they bear a materially higher burden of medical payments plus have access to online tools. These make today’s patient much more demanding with their treatment and requests for off-label use of medical products.

     1. Today’s healthcare environment for patients

      2. Patient expectations

      3. FDA & Industry response

      4. How today’s patient influences off-label promotion of medical products

      5. Patients’ comments

BREAK – 

Session #: 3

Duration: 30 minutes

Learning Objectives: This session will describe the issues that FDA and industry face in making the decisions re off-label promotion of medical products. It will present each side of the equation and will include First Amendment and Fifth Amendment Issues. Court hearings on the subject will be presented.

      1. FDA Position

      2. Industry Position – Is the FDA Listening?

      3. Legal Considerations

      4. Where are we today?

Session #: 4

Duration: 30 minutes 

Learning Objectives: This session will discuss the guidance “Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities” which explains the FDA’s current thinking and recommendations on firms’ communication of health care economic information (HCEI) about approved drugs under section 502(a) of the FD&C Act, which was recently amended by the 21st Century Cures Act.  It also answers common questions and provides the FDA’s recommendations regarding firms’ communications to payors about investigational drugs and devices that are not yet approved or cleared for any use. 

      1. Introduction

      2. Background

      3. Questions & Answers

                  a. Communication of HCEI by Firms to Payors Regarding Approved Drugs

                  b. Communications by Firms to Payors Regarding Investigational Drugs and Devices 

BREAK –

Session #: 5

Duration: 30 minutes 

Learning Objectives: This session will discuss the guidance  “Medical Product Communications That Are Consistent With the FDA-Required Labeling ” which explains the FDA’s current thinking about firms’ medical product communications that include data and information that are not contained in their products’ FDA-required labeling, but that concern the approved or cleared uses of their products.

      1. Introduction

      2. Background

      3. Questions & Answers

Session #: 6

Duration: 30 minutes 

Learning Objectives: This session will discuss comments from industry, health care providers, health care insurers and other concerned parties. The latest legal considerations, decisions and conclusions will be discussed as well as future expectations for off-label promotion of medical products. 

      1. Comments from Industry

      2. Comments from Health Care Providers

      3. Comments from Health Care Insurers

      4. Legal Considerations

      5. Future Expectations

Who will Benefit

•      Quality Managers
•      Quality Engineers
•      Regulatory Affairs
•      Regulatory Attorneys
•      Doctors
•      Health Insurance 
•      Small business owners
•      GxP 
•      Consultants
•      Quality VPs
•      IT VPs
•      Lab Directors
•      Scientists
•      FDA investigators
•      Other regulatory agency investigators
•      Doctors
•      Nurses
•      First Amendment Lawyers
•      Fifth Amendment Lawyers

Industries who can attend

This 180-minute online course is intended for professionals in the Medical Device Industry. Although not presently stated in the draft , the same guide could be used by FDA Regulated Industries personnel.


Speaker Profile

Kelly Thomas

Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations.  Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.  
Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.

Back to Top